Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.
A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.
The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.
The paper is available by clicking here.
More RSI News
RSI paper on Manganese PBPK selected as a top 2017 paper
Each year the Society of Toxicology, Biological Modeling Specialty Section (BMSS) does a literature search to identify outstanding modeling papers in the field of toxicology.…
Read News ItemRSI and Engineers Canada develop on-line training courses
Engineers Canada has retained Risk Sciences International’s (RSI) Climate Group to develop training course modules and to deliver on-line training to Professional Engineers seeking to…
Read News ItemRoger Rempel joins RSI as Director of Climate Group
RSI is pleased to announce that Roger Rempel has joined us as the Director of the RSI Climate Group. Roger is a senior environmental engineer…
Read News ItemNorman Shippee joins RSI
RSI is pleased to announce that Norman Shippee recently joined the team as a Climate and Applications Specialist. Dr. Shippee earned his PhD at the…
Read News Item